Introduction
The prognosis of idiopathic systemic necrotizing relapses and organ damage from vasculitis; on the other hand overtreatment leads to a high drug vasculitis-Wegener's granulomatosis (WG), classical polyarteritis nodosa (CPAN) and microscopic toxicity. With the improved survival with current treatment, morbidity from haemorrhagic cystitis, polyarteritis (MPA)-has been greatly improved by the addition of cyclophosphamide to steroid treatbladder carcinoma and lymphoma has become an important clinical problem.6,8 ment.1-6 Recent studies show that over 80% of patients with WG and over 70% of patients with MPA There are no firm guidelines on the dose or optimum duration of treatment with cyclophosphamsurvive for 5 years.2-7 This relates to an aggressive therapeutic approach, and it has been suggested that ide, or on the least toxic way of administering this drug. There is now evidence that cyclophosphamide patients should be treated with cyclophosphamide for one year or even two years after remission is given as intermittent intravenous pulses together with steroids is of benefit in rheumatoid vasculitis,9 and induced.1,2,6 The question of the optimum duration of treatment is important, as cyclophosphamide and studies in lupus nephritis have shown that a similar regime was more effective in preventing progression steroids have substantial side-effects that have become more important as more patients survive of renal disease, and was less toxic than when these drugs were given on an oral daily basis.10 Several their acute disease. On the one hand, an inadequate duration of treatment might be accompanied by uncontrolled studies have examined the value of pulse intravenous cyclophosphamide in patients with endpoint of the study was drug toxicity, and the secondary endpoints were survival and relapses. a systemic vasculitis, with conflicting results.11-15 To address issues of toxicity, we embarked on a randomized controlled study to compare the effectiveness Randomization and toxicity of our regime of pulse cyclophosphamPatients were randomly assigned to either the conide and prednisolone (PCYP) vs. continuous cyclotinuous or pulse regime by computer-generated phosphamide (followed by azathioprine) and random numbers held in sealed envelopes. The prednisolone (CCAZP) in inducing and maintaining randomization was stratified for renal function (serum a remission in patients with primary systemic vascreatinine <250, 251-500, >500 mmol/l). culitis.
Treatment
The pulse cyclophosphamide and prednisolone Methods regime has been previously reported in detail7,16 and is summarized, together with the continuous treatPatients aged 15-70 years with new-onset systemic ment regime, in the Appendix. In the continuous necrotizing vasculitis were recruited into the study.
arm of the trial (CCAZP), initial treatment was with The definitions used for categorizing patients a tapering dose of oral prednisolone starting at as WG, CPAN and MPA have been described in 0.85 mg/kg and cyclophosphamide. The cyclophosdetail by us16 and resemble those of the Chapel Hill phamide was given until a clinical decision that Consensus Meeting. 17 The diagnosis in each patient remission had been achieved, at which time it was was established by histological evidence of a vasculstopped and azathioprine started. In the pulse regime itis, or radiological evidence of aneurysms in (PCYP), cyclophosphamide and methylprednisolone splanchnic or renal arteries in a patient with a were given intravenously at 0, 2 and 4 weeks. multisystem disorder. All patients had sera tested for Thereafter, the same dose of these agents was given anti-neutrophil cytoplasmic antibodies (ANCA), and as oral pulses over a 3-day period, and the interval the antigenic specificity of these antibodies was between pulses was gradually increased. The protodetermined by ELISAs for anti-proteinase 3 (anti-PR3) col allowed escalation of immunosuppressive treatand anti-myeloperoxidase (anti-MPO) antibodies as ment for severe or life-threatening disease. previously described.18,19 Remission was defined as the absence of clinical symptoms of vasculitis, reso- 
Study protocol
72-1255 mmol/l ( p=0.3)). In patients treated with CCAZP, the median duration of treatment with The trial protocol had institutional ethical approval, and informed consent was obtained from each cyclophosphamide was 3 months (range 1.5-10 months) after which azathioprine was started. patient before enrolment into the study. The primary patients and are summarized in Table 2 . Of patients
with WG, 65% had anti-proteinase 3 (PR3) antibod- ELISA.
Follow-up data
Toxicity and complications CCAZP (Table 4) . Of eight patients with a serum There was slightly more leucopenia (13/30 vs. 7/24, creatinine higher than 500 mmol/l treated with PCYP, p=0.39) in patients treated with CCAZP than in two died, renal function improved in five and patients treated with PCYP. The incidence of infective remained unchanged in one. In 10 patients with the episodes per patient was comparable in the two same degree of renal failure treated with CCAZP, groups, (1.70/patient for PCYP; 1.66/patient for one died and renal function improved in nine. After CCAZP) ( Table 3 ). The other toxicities seen were all a median follow up of 40.4 months, comparable in patients treated with CCAZP, and these were proportions of patients died, relapsed or developed thrombocytopenia (platelet count <100×109/l) in end-stage renal failure in the two treatment groups three patients, steroid-induced diabetes in one (Table 4 and Figure 1 ). The median rise in BVAS at patient, osteoporosis in one patient and a basal-cell relapse was 6 (range 1-17). The three-year patient carcinoma in one patient. Two patients in the CCAZP survival of 77% in patients on PCYP did not differ group died from septicaemia, one from a pancreatitis significantly from that of 90% in patients treated and one from a bronchial neoplasm.
with CCAZP, ( p=0.38) (Figure 1 ). There were no significant differences between the two treatment Remission and relapse groups in the serum creatinine (Figure 2 ), disease activity scores (Birmingham vasculitis activity score) Using BVAS score and the definitions in the methods, 8 (33.3%) patients treated with PCYP and 7 (23.3%) (Figure 3 ), CRP and vWF (data not shown) at followup. The rate of fall of disease activity and serum treated with CCAZP went into complete remission. Partial remission was achieved in 12 (50%) patients creatinine was most marked in the first 3 months of therapy. treated with PCYP and in 19 (63.3%) patients on whiskers extend to the upper and lower adjacent values. There were no differences between PCYP and CCAZP in the serum creatinine.
Escalation treatment
This was allowed in the protocol as clinically indiDiscussion cated. It was used in 31 patients in total. In patients The key clinical question addressed was whether treated with PCYP, eight received plasma exchange, pulse cyclophosphamide was less toxic than continufive intravenous methylprednisolone and eight intraous oral cyclophosphamide and azathioprine in venous immunoglobulin. In addition, 13 patients treating vasculitis. In order to detect a reduction in were given continuous oral prednisolone. In patients toxicity from 70 to 40%, with a power of 80% and on CCAZP, 12 received plasma exchange, eight a significance at the 5% level, 42 patients would be intravenous methylprednisolone and five intravenous required in each treatment arm. Because the trial immunoglobulin.
was small, although no statistically significant differences in toxicity were detected, smaller differences Deaths that might be important could exist between the treatments. Septicaemia was the cause of death in two patients in the CCAZP group, while pancreatitis and bronchial
The present study included patients with Wegener's granulomatosis and microscopic polyartneoplasm accounted for the two other deaths in this group. In the pulse group, two patients died early eritis, which are primary systemic vasculitides with predominant small-vessel involvement, as well as (within 3 months) with active vasculitis. Of the later deaths, two were from myocardial ischaemia and classical polyarteritis with medium-vessel involvement. At the time the study was started, microscopic one from a pulmonary embolus.
cyclophosphamide and prednisolone, with or without azathioprine. Steroids and cyclophosphamide are widely used for remission induction in systemic vasculitis, with the steroids being tapered and cyclophosphamide maintained for a variable period after remission is induced.1,6 Although leading to longterm remissions in what were once usually fatal diseases,1 this regime is not supported by controlled study. The early NIH studies by Fauci et al.1 recommended treatment with oral cyclophosphamide for one year after remission had been induced. As more patients survive in systemic vasculitis, a major problem now is the long-term toxicity of continuous oral cyclophosphamide and also of prednisolone. In their after 3 months than in the CCAZP group but the differences found that drug-related toxicity had become a major were not significant. cause of morbidity. Forty-three percent of patients developed cyclophosphamide-induced cystitis, 2.8% a bladder cancer, 2% lymphomas, 2% myelodysplapolyarteritis was not clearly differentiated from classia and 57% of the women, ovarian failure. Overall sical polyarteritis17 and indeed this issue is still there was a 2.4-fold increase in malignancies, a debated.21 We grouped these three disorders because 33-fold excess risk of bladder cancer and an 11-fold they have in common a vasculitis. The current excess risk of lymphoma, compared with age-ECSYSVASTRIAL study has also grouped patients with matched controls. Despite this very significant treatWegener's granulomatosis and microscopic polyartment toxicity from cyclophosphamide, the patients eritis.22 still had active disease for 54% of the total time of Disease activity was scored prospectively using follow-up, and there is the additional toxicity from the Birmingham vasculitis activity score and because prednisolone. this was then being validated,20 it was not used to
The main justification for the present study was alter management. The BVAS score, however, to find safer therapies for the treatment of vasculitis. enabled us to compare objectively the responses to
In uncontrolled studies in the UK, cyclophosphamide treatment in these two groups of patients and also has been substituted by azathioprine for the maintenthe relapse rates. The BVAS score also enabled us to ance of remission3,4,7 to minimize cyclophosphamide define remission and relapse, and although these toxicity, and this regime was used in one arm of the definitions were arbitrary, the international validation present study. Whether prednisolone and long-term and extension of this score23 will allow comparison cyclophosphamide, or prednisolone and cyclophosof our results with those of future studies.
phamide with conversion to azathioprine when The aims of treatment of systemic vasculitis are remission is induced, are comparable in terms of firstly, to induce remission of active disease and efficacy and toxicity is not known, and is currently improve survival; secondly, to limit disease-related being investigated by the multicenter morbidity; and thirdly, to maintain remission, thereby ECSYSVASTRIAL trial.22 The pulse regime in this preventing organ damage from relapses. Now that study has been used in the UK for the treatment of most patients with a systemic vasculitis survive their rheumatoid vasculitis9 and systemic vasculitis.7 The acute illness, an important fourth aim is to limit the initial three pulses are given intravenously and subconsequences of the toxicity of treatment with cyclosequently by mouth. The rationale was that by giving phosphamide and steroids. Most would agree that both prednisolone and cyclophosphamide intermitthe addition of cyclophosphamide to steroids as tently, overall toxicity from immunosuppression originally reported by Fauci et al.1 in patients with would be diminished. This differs from other pulse Wegener's granulomatosis has greatly improved the regimes used in systemic vasculitis in which cycloprognosis of patients with all types of primary sysphosphamide is given intermittently intravenously temic vasculitis and the only controlled study in and the steroids administered continuously.11-15 patients with classical polyarteritis and Churg Strauss These regimes have also not been validated in a syndrome confirmed this.5 Our study, together with controlled trial. Our study set out to compare a that of Guillevin et al. (submitted for publication), is continuous regime which was being used in the UK the first controlled study to investigate the optimum dose and routes of administration of treatment with with our pulse regime. We did not set out to determine whether cyclophosphamide given interpatients was due to azathioprine. With the limitations imposed by the number of patients in each treatment mittently intravenously was as safe and as effective group, we found that pulse cyclophosphamide and as cyclophosphamide given continuously on a backsteroids were as effective in inducing remission (as ground of the same dose of continuous prednisolone.
assessed by BVAS20 and CRP and improving renal This is a valid question which must be determined function) as continuous cyclophosphamide and sterseparately by controlled study. We accept that steroid oids. Improvement of renal function was comparable dosages in the two regimes in the present study between the two treatments in patients with initial differed and that this might have contributed to the severe renal impairment. Survival did not differ differences seen.
significantly between treatment regimes, with 77% Previous studies in lupus nephritis showed that of patients treated with PCYP and 90% of patients pulse cyclophosphamide was as effective in improvtreated with CCAZP surviving for 3 years. The overall ing and stabilizing renal function and less toxic than survival in this study is comparable to that of other continuous oral cyclophosphamide.10 Uncontrolled studies of patients with a vasculitis treated with studies of pulse cyclophosphamide, usually with continuous oral prednisolone and long-term oral daily prednisolone, in patients with systemic vasculcyclophosphamide.2,6 The data from this study sugitis, have yielded contradictory findings. Early studies gest that prednisolone and short-term cyclophosin systemic rheumatoid vasculitis suggested that an phamide with conversion to azathioprine on initial three-weekly pulse regime was more effective remission, or pulse cyclophosphamide and prednisothan continuous oral treatment with these agents. 9 lone, is no less effective in treating vasculitis than Falk et al.12 in a retrospective study in patients with the long-term cyclophosphamide used in other stud-ANCA-positive glomerulonephritis and systemic vasies.2,6 We also believe that these regimes are likely culitis, showed that monthly intravenous cyclophosto be less toxic than long-term continuous oral phamide for 6 months, and continuous oral cyclophosphamide. The ECSYSVASCTRIAL group is prednisolone (15 patients) was as effective as concurrently comparing continuous oral prednisolone tinuous oral cyclophosphamide and prednisolone and long-term cyclophosphamide with continuous (30 patients) in terms of renal and patient survival.
oral prednisolone and cyclophosphamide with early Similarly, Haubitz et al. 13 found that all eight patients conversion to azathioprine on remission.22 A further with Wegener's granulomatosis treated with monthly question that needs to be addressed is whether pulse intravenous cyclophosphamide and oral daily prednicyclophosphamide is as effective and less toxic than solone went into remission, and that drug toxicity continuous oral cyclophosphamide when given on was less than in 15 patients treated with continuous a background of the same dose of continuous oral oral cyclophosphamide and prednisolone. By conprednisolone. trast Hoffman et al.14 found that only 2/11 (18%)
In any controlled trial of therapy the question of patients with Wegener's granulomatosis treated with escalation treatment poses difficulties in the analysis monthly pulse cyclophosphamide and oral daily of the efficacy of trial agents. In a recent round-table prednisolone achieved sustained remission. A similar discussion by participants from 15 European centres, disappointing outcome was observed by Steppat and all used additional therapy in the form of intravenous Gross11 and by In the latter methylprednisolone, plasma exchange or intravenous study of 43 patients, only seven were new patients, immunoglobulin for patients with severe vasculitis.22 and overall 42% of the whole group responded to
In the present study, escalation treatment was used treatment with pulse cyclophosphamide. The nonin slightly more patients treated with PCYP (15/24) responders had more severe disease, were less likely than in patients treated with CCAZP (16/30). Together to have disease restricted to the upper respiratory with the requirement for continuous oral prednisotract, and were also more likely to have higher ANCA lone in 13 patients treated with PCYP, this does titres than were responders. The above studies, suggest that this regime was less effective in treating although uncontrolled, led to a widespread percepvasculitis than CCAZP. Clearly the use of additional tion that pulse cyclophosphamide was less effective treatment could obscure differences between the two than continuous cyclophosphamide, especially in treatments studied, but it would be impossible to patients with severe disease.
deny patients accepted additional therapies in the In the present study, patients treated with presence of potentially life-threatening disease. pulse PCYP had fewer episodes of leucopenia than Relapses in the short term were comparable in patients treated with CCAZP, although the differences the two treatment regimes. Two recent studies have were not significant. The incidence of infection was highlighted the problem of relapses in patients with comparable with the two treatment regimes. There a systemic vasculitis. This has become apparent as were no episodes of haemorrhagic cystitis. It is likely more patients survive their acute illness. MESNA is to be given in 3 oral doses totalling 75% of the dose of cyclophosphamide for every dose of intravenous cyclophosphamide. Dose adjustments are advised for the following reasons: 1) Maximum doses: The maximum bolus dose of cyclophosphamide, regardless of weight, will be 1000 mg.
The maximum bolus dose of prednisolone regardless of weight will be 1000 mg.
